Literature DB >> 22194600

Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer.

Victoria Cohen-Kaplan1, Jenny Jrbashyan, Yoav Yanir, Inna Naroditsky, Ofer Ben-Izhak, Neta Ilan, Ilana Doweck, Israel Vlodavsky.   

Abstract

Activity of heparanase is implicated strongly in dissemination of metastatic tumor cells and cells of the immune system. In addition, heparanase enhances the phosphorylation of selected signaling molecules, including SRC and EGFR, in a manner that requires secretion but not enzymatic activity of heparanase and is mediated by its C-terminal domain. Clinically, heparanase staining is associated with larger tumors and increased EGFR phosphorylation in head and neck carcinoma. We hypothesized that signal transducer and activator of transcription (STAT) proteins mediate the protumorigenic function of heparanase downstream of the EGFR. We provide evidence that heparanase enhances the phosphorylation of STAT3 and STAT5b but not STAT5a. Moreover, enhanced proliferation of heparanase transfected cells was attenuated by STAT3 and STAT5b siRNA, but not STAT5a or STAT1 siRNA. Clinically, STAT3 phosphorylation was associated with head and neck cancer progression, EGFR phosphorylation, and heparanase expression and cellular localization. Notably, cytoplasmic rather than nuclear phospho-STAT3 correlated with increased tumor size (T-stage; p = 0.007), number of metastatic neck lymph nodes (p = 0.05), and reduced survival of patients (p = 0.04).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22194600      PMCID: PMC3307274          DOI: 10.1074/jbc.M111.271346

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

Review 1.  Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Authors:  Stephen Y Lai; Faye M Johnson
Journal:  Drug Resist Updat       Date:  2010-05-14       Impact factor: 18.500

Review 2.  NF-kappaB and STAT3 signaling in glioma: targets for future therapies.

Authors:  George P Atkinson; Susan E Nozell; Etty Tika N Benveniste
Journal:  Expert Rev Neurother       Date:  2010-04       Impact factor: 4.618

3.  Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity.

Authors:  Flonia Levy-Adam; Sari Feld; Victoria Cohen-Kaplan; Anna Shteingauz; Miriam Gross; Gil Arvatz; Inna Naroditsky; Neta Ilan; Ilana Doweck; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

Review 4.  Tumorigenic and adhesive properties of heparanase.

Authors:  Flonia Levy-Adam; Neta Ilan; Israel Vlodavsky
Journal:  Semin Cancer Biol       Date:  2010-07-07       Impact factor: 15.707

5.  Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.

Authors:  Eirini Pectasides; Ann-Marie Egloff; Clarence Sasaki; Panteleimon Kountourakis; Barbara Burtness; George Fountzilas; Urania Dafni; Thomas Zaramboukas; Theodoros Rampias; David Rimm; Jennifer Grandis; Amanda Psyrri
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

Review 6.  Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Ilana Dowek; Ralph D Sanderson; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

Review 7.  Emerging drugs to treat squamous cell carcinomas of the head and neck.

Authors:  Christopher Fung; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

8.  A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Gil Arvatz; Svetlana Gingis-Velitski; Flonia Levy-Adam; Ofer Nativ; Ronen Shemesh; Michal Ayalon-Sofer; Neta Ilan; Israel Vlodavsky
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

9.  The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.

Authors:  K Dredge; E Hammond; K Davis; C P Li; L Liu; K Johnstone; P Handley; N Wimmer; T J Gonda; A Gautam; V Ferro; I Bytheway
Journal:  Invest New Drugs       Date:  2009-04-09       Impact factor: 3.850

Review 10.  Heparanase: busy at the cell surface.

Authors:  Liat Fux; Neta Ilan; Ralph D Sanderson; Israel Vlodavsky
Journal:  Trends Biochem Sci       Date:  2009-09-03       Impact factor: 13.807

View more
  26 in total

1.  Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence.

Authors:  Anjum Riaz; Neta Ilan; Israel Vlodavsky; Jin-Ping Li; Staffan Johansson
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

2.  Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity.

Authors:  Y Yang; C Gorzelanny; A T Bauer; N Halter; D Komljenovic; T Bäuerle; L Borsig; M Roblek; S W Schneider
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

3.  Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth.

Authors:  Miriam Gross-Cohen; Sari Feld; Ilana Doweck; Gera Neufeld; Peleg Hasson; Gil Arvatz; Uri Barash; Inna Naroditsky; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2016-03-24       Impact factor: 12.701

4.  Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and α-actinin.

Authors:  Anna Shteingauz; Neta Ilan; Israel Vlodavsky
Journal:  Cell Mol Life Sci       Date:  2014-05-01       Impact factor: 9.261

Review 5.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

Review 6.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

7.  Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy.

Authors:  Anna Shteingauz; Ilanit Boyango; Inna Naroditsky; Edward Hammond; Maayan Gruber; Ilana Doweck; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2015-08-06       Impact factor: 12.701

8.  Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice.

Authors:  Immanuel Lerner; Eyal Zcharia; Tzahi Neuman; Esther Hermano; Ariel M Rubinstein; Israel Vlodavsky; Michael Elkin
Journal:  Cell Mol Life Sci       Date:  2013-10-30       Impact factor: 9.261

9.  Heparanase cooperates with Ras to drive breast and skin tumorigenesis.

Authors:  Ilanit Boyango; Uri Barash; Inna Naroditsky; Jin-Ping Li; Edward Hammond; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2014-06-26       Impact factor: 12.701

10.  Heparanase enhances myeloma progression via CXCL10 downregulation.

Authors:  U Barash; Y Zohar; G Wildbaum; K Beider; A Nagler; N Karin; N Ilan; I Vlodavsky
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.